
Annual report 2024
added 04-11-2026
Medigus Ltd. Revenue 2011-2026 | MDGS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Medigus Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.9 M | 91.7 M | 91.9 M | 10.1 M | 531 K | 273 K | 436 K | 467 K | 549 K | 619 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91.9 M | 273 K | 22.6 M |
Quarterly Revenue Medigus Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54 K | - | - | - | 82 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82 K | 54 K | 68 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
4 B | $ 184.65 | 2.2 % | $ 13.8 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
AxoGen
AXGN
|
225 M | $ 34.7 | 3.66 % | $ 1.6 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.44 | 0.97 % | $ 1.68 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 290.0 | 0.64 % | $ 8.18 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.58 | -0.6 % | $ 36.1 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 40.53 | 3.79 % | $ 6.04 K | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.33 | 0.15 % | $ 125 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 63.5 | 0.51 % | $ 94 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 10.34 | 3.3 % | $ 293 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
64 M | $ 24.95 | - | $ 211 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Inogen
INGN
|
349 M | $ 6.56 | 1.71 % | $ 175 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | 0.97 % | $ 17.6 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 93.82 | 0.9 % | $ 12.7 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.03 | -0.19 % | $ 1.23 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.34 | 1.4 % | $ 919 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.98 | 1.01 % | $ 71.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.04 | 0.56 % | $ 400 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.66 | 2.01 % | $ 382 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.74 | 1.44 % | $ 31 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 55.86 | 1.79 % | $ 1.64 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 39.17 | 1.85 % | $ 1.22 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 65.23 | 1.01 % | $ 3.56 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 88.7 | 1.11 % | $ 3.08 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.7 | -0.05 % | $ 123 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 78.25 | 0.17 % | $ 45.8 B |